- Barrons.com•10 days ago
Entities controlled by Foresite Capital sold 50,000 shares of Aerie Pharmaceuticals (AERI) for $2,016,995, or an average of $40.34 a share, on Oct. 6. Two weeks earlier, the biotech announced a successful Phase 3 trial for its glaucoma treatment candidate, Roclatan, sending the stock on a multi-session rally. Foresite’s indirectly held stake in Aerie had topped the 10% mark in late July, making the private-equity firm a reporting entity subject to regulatory filings.
- Benzinga•17 days ago
Cantor Fitzgerald reiterated its Buy rating and $50 price target on Aerie Pharmaceuticals Inc (NASDAQ: AERI ), as the company provided new clinical data to clear up residual misconceptions and uncertainties ...
- Zacks•20 days ago
These 6 pharma and biotech stocks had an impressive run in September thanks to acquisition announcements, positive clinical trial announcements and FDA approvals.
Aerie Pharmaceuticals, Inc. (AERI)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||35.00 x 14900|
|Ask||37.88 x 1000|
|Day's Range||35.55 - 36.38|
|52wk Range||10.82 - 41.72|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-11.31|
|Avg Vol (3m)||1,135,800|
|Dividend & Yield||N/A (N/A)|